

## PRESS RELEASE

# Cordlife Becomes First Cord Blood Bank in Indonesia to Achieve Global AABB Accreditation

### Key points:

- Cordlife Group Limited's subsidiary in Indonesia, PT. Cordlife Persada, has achieved the prestigious AABB accreditation for its cord blood banking facility, the first in the country to receive a global accreditation.
- All of Cordlife's seven cord blood banking facilities are now AABB accredited.

**Singapore, 6 November 2019** – Singapore Exchange mainboard listed Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), announced today that its subsidiary, PT. Cordlife Persada (“**Cordlife Indonesia**” or the “**Company**”), has become the first in Indonesia to join the ranks of world-class cord blood banks as an AABB accredited facility, a testament of the Group's commitment to providing the highest quality service to help expectant families store their babies' cord blood for future medical use.

AABB is the global leader in standards development and its accreditation program promotes the highest standards of care for both patients and donors. It covers all aspects of blood banking, transfusion medicine, haematopoietic, cord blood and other cellular therapies. The accreditation was awarded to Cordlife Indonesia after the Company was determined to have met or exceeded the stringent standards set by AABB, following a rigorous on-site audit conducted by trained AABB assessors.

Cordlife owns the largest network of cord blood banks in Asia. They currently operate seven facilities in six Asian countries, namely Singapore, Indonesia, Malaysia, Hong Kong, India and the Philippines. Along with Cordlife Indonesia's latest achievement, all cord blood banking facilities under the Group are fully accredited by AABB.

“Since day one, we have been very focused on ensuring that our clients are given world-class quality and reliable cord blood banking services wherever we operate. We are extremely excited to be the first cord blood bank in Indonesia to be AABB accredited. This accreditation label is vital in helping physicians ascertain the quality of the cord blood to be used in a transplant or infusion,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife.

Cord blood banking is deemed as essential by many expectant parents because cord blood contains stem cells that have already been proven useful in the treatment of over 80 conditions, which include leukaemia, lymphoma and thalassemia major. Researchers around the world are also investigating the effectiveness of using cord blood for other conditions such as autism, spinal cord injury and cerebral palsy. Once any of these research advances to reality, parents who have stored cord blood for their children will have more medical options when the need arises.

To date, Cordlife has already performed 56 cord blood releases to 15 healthcare institutions in 10 countries, at the request of their clients. The majority of the cord blood was used for cerebral palsy, followed by thalassemia major and autism. With Cordlife Indonesia's new AABB accreditation status, Cordlife clients in Indonesia can now opt to have their transplant or infusion done in countries such as United States and Singapore, where only cord blood units (if imported) handled by AABB or its equivalent accredited facilities, will be permitted or preferred for use.

"Accreditation is highly crucial for healthcare organisations because it gives patients the necessary peace of mind. Expectant parents who choose an accredited cord blood bank can be assured that their babies' cord blood will be properly handled and cryopreserved for future use," said Dr Ardiansjah Dara, SpOG, a renowned obstetrician and gynaecologist in Indonesia.

**## End ##**

### **ABOUT PT. CORDLIFE PERSADA**

PT. Cordlife Persada ("Cordlife Indonesia" or the "Company") is a majority-owned subsidiary of Cordlife Group Limited. Established in Indonesia since 2003, Cordlife Indonesia is the first company to operate a full-fledged cord blood and cord lining processing and storage facility in the country. The Company is the industry market leader in Indonesia, according to Deloitte.<sup>1</sup> In 2019, Cordlife Indonesia upgraded to a new facility located in Central Jakarta with a storage capacity for up to 70,000 stem cell units. This facility is currently the largest in Indonesia and the first and only to be accredited by AABB. Cordlife Indonesia's new facility also features dedicated laboratory areas, which can be used by the company to perform clinical genetic testing locally such as non-invasive prenatal testing and preimplantation genetic diagnosis. For more information, visit [www.cordlife.co.id](http://www.cordlife.co.id).

### **ABOUT CORDLIFE GROUP LIMITED**

Incorporated in 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer healthcare group and one of the key providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets, namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Through its marketing agents, Cordlife also expanded its presence to Myanmar and Vietnam in 2017 as well as Bangladesh in 2019.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group's facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby are also two of the four cord blood banks in Asia, and seven in the world, to be accredited by both AABB and FACT, another world-class accreditation body for cord blood banks globally.

In the area of clinical diagnostics, Cordlife India, Healthbaby and Hong Kong Screening Centre are accredited by the College of American Pathologists ("CAP"). These quality achievements underpin the Group's commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

### **ABOUT AABB**

AABB is an international, not-for-profit association representing individuals and institutions involved in the fields of transfusion medicine and cellular therapies. The association is committed to improving health through the development and delivery of standards, accreditation and educational programs that focus on optimising patient and donor care and safety. AABB membership includes physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. AABB members are located in more than 80 countries and AABB accredits institutions in over 50 countries.

---

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR Pte Ltd  
4 Robinson Road #04-01  
The House of Eden  
Singapore 048543

CONTACT : Mr Ngo Yit Sung / Mr Benjamin Tho

OFFICE : (65) 6438 2990

EMAIL : [yitsung@financialpr.com.sg](mailto:yitsung@financialpr.com.sg) / [benjamin@financialpr.com.sg](mailto:benjamin@financialpr.com.sg)